[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP7084313B2 - アマニチンコンジュゲート - Google Patents

アマニチンコンジュゲート Download PDF

Info

Publication number
JP7084313B2
JP7084313B2 JP2018546006A JP2018546006A JP7084313B2 JP 7084313 B2 JP7084313 B2 JP 7084313B2 JP 2018546006 A JP2018546006 A JP 2018546006A JP 2018546006 A JP2018546006 A JP 2018546006A JP 7084313 B2 JP7084313 B2 JP 7084313B2
Authority
JP
Japan
Prior art keywords
linker
hdp
cancer
antibody
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018546006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511484A (ja
Inventor
ルッツ クリスティアン
アンデール ヤン
ミュラー クリストフ
ジーモン ベルナー
ベルナー－ジーモン ズザンネ
ヘヒラー トシュテン
クルケ ミヒャエル
Original Assignee
ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2019511484A publication Critical patent/JP2019511484A/ja
Priority to JP2021182011A priority Critical patent/JP7362714B2/ja
Application granted granted Critical
Publication of JP7084313B2 publication Critical patent/JP7084313B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
JP2018546006A 2016-03-03 2017-03-02 アマニチンコンジュゲート Active JP7084313B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021182011A JP7362714B2 (ja) 2016-03-03 2021-11-08 アマニチンコンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16000511.2A EP3222292A1 (en) 2016-03-03 2016-03-03 Amanitin conjugates
EP16000511.2 2016-03-03
PCT/EP2017/054911 WO2017149077A1 (en) 2016-03-03 2017-03-02 Amanitin conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021182011A Division JP7362714B2 (ja) 2016-03-03 2021-11-08 アマニチンコンジュゲート

Publications (2)

Publication Number Publication Date
JP2019511484A JP2019511484A (ja) 2019-04-25
JP7084313B2 true JP7084313B2 (ja) 2022-06-14

Family

ID=55456549

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018546006A Active JP7084313B2 (ja) 2016-03-03 2017-03-02 アマニチンコンジュゲート
JP2021182011A Active JP7362714B2 (ja) 2016-03-03 2021-11-08 アマニチンコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021182011A Active JP7362714B2 (ja) 2016-03-03 2021-11-08 アマニチンコンジュゲート

Country Status (25)

Country Link
US (2) US11590238B2 (da)
EP (2) EP3222292A1 (da)
JP (2) JP7084313B2 (da)
KR (1) KR102466933B1 (da)
CN (1) CN108778341B (da)
AU (1) AU2017228020B2 (da)
BR (1) BR112018067615A2 (da)
CA (1) CA3015138A1 (da)
CL (1) CL2018002502A1 (da)
CO (1) CO2018009533A2 (da)
DK (1) DK3423104T5 (da)
ES (1) ES2925006T3 (da)
HR (1) HRP20220948T1 (da)
HU (1) HUE059360T2 (da)
LT (1) LT3423104T (da)
MX (1) MX2018010247A (da)
NZ (1) NZ745508A (da)
PL (1) PL3423104T3 (da)
PT (1) PT3423104T (da)
RS (1) RS63451B1 (da)
RU (1) RU2753416C2 (da)
SG (2) SG10201913942SA (da)
SI (1) SI3423104T1 (da)
WO (1) WO2017149077A1 (da)
ZA (1) ZA201805336B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017204139B2 (en) 2016-06-17 2018-08-09 Vor Biopharma, Inc. Compositions and methods for the depletion of cells
AU2017380099B2 (en) 2016-12-23 2024-07-11 Heidelberg Pharma Research Gmbh Amanitin antibody conjugates
AU2018209452B2 (en) 2017-01-20 2024-11-07 Heidelberg Pharma Research Gmbh Compositions and methods for the depletion of CD137+ cells
CN114191564A (zh) * 2017-08-18 2022-03-18 四川百利药业有限责任公司 一种非天然鹅膏毒肽类抗体偶联物
KR20190043031A (ko) * 2017-10-17 2019-04-25 한국화학연구원 아마톡신 유도체 및 이의 제조방법
WO2019090242A1 (en) * 2017-11-04 2019-05-09 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
EP3740233A4 (en) * 2018-01-18 2021-11-24 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD134 + CELLS
JP2021521202A (ja) * 2018-04-13 2021-08-26 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング 固形腫瘍の治療のための標的化されたアマトキシン複合体
EP3801635A4 (en) * 2018-06-07 2022-04-06 Magenta Therapeutics, Inc. THERAPEUTIC METHODS USING ANTIBODY-DRUG CONJUGATE (ADC)
CA3107383A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
CN112739339A (zh) * 2018-07-23 2021-04-30 美真达治疗公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
WO2020127968A1 (en) 2018-12-20 2020-06-25 Marino Stephen F Protein-drug conjugate comprising a monomeric form of proteinase 3
CA3125751A1 (en) * 2019-01-07 2020-07-16 Magenta Therapeutics, Inc. Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy
EP3958908A1 (en) * 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin antibody-drug conjugates and uses thereof
BR112021023226A2 (pt) 2019-05-23 2022-01-04 Heidelberg Pharma Res Gmbh Composto, conjugado, método para sintetizar os conjugados e composição farmacêutica
EP3792250A1 (en) * 2019-09-13 2021-03-17 Pure Bioorganics SIA Synthesis of alpha-amanitin and its derivatives
US20220298204A1 (en) * 2019-07-05 2022-09-22 Pure Bioorganics Sia Synthesis of a-amanitin and its derivatives
AR120218A1 (es) * 2019-10-15 2022-02-02 Heidelberg Pharma Res Gmbh Conjugados de amatoxina y anticuerpo específico de linfocitos b
EP4161946A1 (en) * 2020-06-09 2023-04-12 Heidelberg Pharma Research GmbH Method for synthesis of thioether-containing peptides
CA3195572A1 (en) 2020-11-04 2022-05-12 Heidelberg Pharma Research Gmbh Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy
CN116615219A (zh) * 2020-12-22 2023-08-18 中外制药株式会社 包括利用混合溶剂的冷冻干燥工序的药品的制造方法
AR125130A1 (es) 2021-03-19 2023-06-14 Heidelberg Pharma Res Gmbh Conjugados de amatoxina y anticuerpo específicos de linfocitos b
US20240165257A1 (en) 2022-11-01 2024-05-23 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519906A (ja) 2012-06-04 2015-07-16 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ 部位特異的標識法およびそれによって生成される分子
JP2015533490A (ja) 2012-09-12 2015-11-26 ジェンザイム・コーポレーション 変更されたグリコシル化および低減されたエフェクター機能を有するＦｃ含有ポリペプチド

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
ATE521366T1 (de) 2006-05-27 2011-09-15 Faulstich Heinz Dr Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
CL2009000505A1 (es) 2008-03-05 2010-01-15 Biocryst Pharm Inc Compuestos derivados de triciclos nitrogenados, inhibodores de polimerasas de adn y arn virales; composicion farmaceutica que los comprende; y uso en el tratamiento de infecciones virales y cancer.
KR20110140124A (ko) 2009-04-08 2011-12-30 하인즈 파울스티히 암치료용 아미톡신-활성 표적 결합 부위
SI3192529T1 (sl) 2009-04-08 2020-07-31 Faulstich, Heinz Dr. Z amatoksinom ojačane vezne komponente terapevtske celične površine, zasnovane za zdravljenje tumorjev
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
CN102933236B (zh) 2010-04-15 2014-10-08 斯皮罗根有限公司 吡咯并苯二氮卓类及其结合物
ES2402254T3 (es) * 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
EP2684865A1 (en) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
CN105377304B (zh) * 2014-03-10 2018-05-15 海德堡医药有限责任公司 鹅膏毒肽衍生物
BR112017019300B1 (pt) * 2015-03-09 2023-02-23 Heidelberg Pharma Gmbh Conjugado de fórmula genérica (ama l x s)n ab, método para sintetizar um conjugado de fórmula genérica (ama l x s)n ab, kit, composição farmacêutica e uso da composição farmacêutica
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519906A (ja) 2012-06-04 2015-07-16 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ 部位特異的標識法およびそれによって生成される分子
JP2015533490A (ja) 2012-09-12 2015-11-26 ジェンザイム・コーポレーション 変更されたグリコシル化および低減されたエフェクター機能を有するＦｃ含有ポリペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIANG ZHAO et al.，SYNTHESIS OF A CYTOTOXIC AMANITIN FOR BIORTHOGONAL CONJUGATION，CHEMBIOCHEM，ドイツ，2015年06月03日，Vol.16，pp.1420-1425，http://dx.doi.org/10.1002/cbic.201500226

Also Published As

Publication number Publication date
JP2019511484A (ja) 2019-04-25
KR20180114191A (ko) 2018-10-17
HRP20220948T1 (hr) 2022-10-28
EP3423104A1 (en) 2019-01-09
NZ745508A (en) 2023-05-26
US20230233703A1 (en) 2023-07-27
KR102466933B1 (ko) 2022-11-11
JP2022028756A (ja) 2022-02-16
ES2925006T3 (es) 2022-10-13
EP3222292A1 (en) 2017-09-27
DK3423104T5 (da) 2022-09-05
PT3423104T (pt) 2022-08-22
JP7362714B2 (ja) 2023-10-17
RU2753416C2 (ru) 2021-08-16
CO2018009533A2 (es) 2018-09-20
WO2017149077A1 (en) 2017-09-08
BR112018067615A2 (pt) 2018-12-26
AU2017228020B2 (en) 2024-05-16
DK3423104T3 (da) 2022-08-29
HUE059360T2 (hu) 2022-11-28
US11590238B2 (en) 2023-02-28
RS63451B1 (sr) 2022-08-31
SG10201913942SA (en) 2020-03-30
US20210138081A1 (en) 2021-05-13
RU2018131636A3 (da) 2020-04-08
PL3423104T3 (pl) 2022-09-19
ZA201805336B (en) 2023-09-27
EP3423104B1 (en) 2022-05-18
MX2018010247A (es) 2018-12-19
AU2017228020A1 (en) 2018-09-06
LT3423104T (lt) 2022-08-10
RU2018131636A (ru) 2020-04-03
SI3423104T1 (sl) 2022-09-30
CN108778341B (zh) 2022-11-01
CA3015138A1 (en) 2017-09-08
CL2018002502A1 (es) 2019-02-22
SG11201807472TA (en) 2018-09-27
CN108778341A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
JP7084313B2 (ja) アマニチンコンジュゲート
KR102674750B1 (ko) 신규한 아마니틴 합성 방법
US11926631B2 (en) Method of treating cancer using amanitin derivatives
US10723766B2 (en) Derivatives of gamma-amanitin
RU2792210C2 (ru) Новый способ синтеза аманитинов
NZ785704A (en) Novel amanitin conjugates

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211108

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211108

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211228

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220602

R150 Certificate of patent or registration of utility model

Ref document number: 7084313

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150